Repatha vs Leqvio Real-World Evidence Comparison

How Each Drug Works

Both drugs lower LDL-C by increasing the number of LDL receptors on liver cells. The similarity stops there.

Evolocumab is a fully human monoclonal IgG2 antibody. It binds circulating PCSK9 protein directly, preventing PCSK9 from binding to and degrading LDL receptors. Because the protein itself is being cleared, the drug must be re-dosed every 14 days (140 mg) or every 28 days (420 mg via auto-injector or infusion device) to maintain suppression. Roughly 12 hours after a missed dose, free PCSK9 begins to recover, and LDL-C starts rising again.

Inclisiran takes a completely different route. It is a small interfering RNA (siRNA) conjugated to GalNAc, which targets it to hepatocytes. Once inside the cell, it enters the RNA-induced silencing complex (RISC) and cleaves PCSK9 messenger RNA before it can be translated into protein. Because RISC remains active for months, a single injection suppresses hepatic PCSK9 synthesis for approximately six months. The approved schedule is an injection on day 1, day 90, then every 180 days thereafter. That translates to two injections per year in steady state.

Why Mechanism Matters Clinically

The mechanism gap matters most when you are thinking about adherence and missed doses. Miss a biweekly evolocumab injection and LDL-C rebounds within days. Miss an inclisiran dose by three or four weeks and the residual RISC activity continues providing meaningful suppression. This pharmacological forgiveness is one reason payers and health systems are increasingly interested in inclisiran as an in-office, administered therapy rather than a patient self-inject regimen.

Protein Blocking vs. Gene Silencing

One subtle clinical distinction: evolocumab lowers circulating PCSK9 protein levels by roughly 70-80%, while inclisiran reduces hepatic PCSK9 mRNA and subsequently circulating PCSK9 protein by up to 90% in some studies. Despite deeper PCSK9 protein suppression with inclisiran, the net LDL-C reduction between the two agents is comparable, likely because LDL receptor recycling is already near-maximal at 50-60% LDL-C lowering. Additional PCSK9 suppression beyond that threshold produces diminishing returns at the receptor level.

Landmark Trial Data: What the Numbers Actually Show

FOURIER: The Definitive Evolocumab Outcomes Trial

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) who were already on statin therapy [1]. Baseline LDL-C was 92 mg/dL. At 48 weeks, evolocumab 140 mg every two weeks reduced LDL-C by 59% vs. Placebo, bringing median LDL-C to 30 mg/dL. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% over a median 2.2 years (hazard ratio 0.85, 95% CI 0.79-0.92, P<0.001). Myocardial infarction risk fell by 27% and stroke by 21%. Adverse event rates were similar to placebo, with no increase in neurocognitive events, hepatic toxicity, or diabetes incidence.

ORION-10 and ORION-11: Inclisiran's Key LDL-C Data

ORION-10 (N=1,561, U.S. Patients with ASCVD) and ORION-11 (N=1,617, patients with ASCVD or ASCVD risk equivalents, European/U.S.) together provided the efficacy foundation for FDA approval [2]. Across both trials, inclisiran 284 mg reduced time-averaged LDL-C by 52% compared with placebo over 18 months. At day 510 (the last on-treatment visit), LDL-C was lowered by 54% in ORION-10 and 50% in ORION-11. Injection-site reactions occurred in 2.6% of inclisiran patients vs. 0.9% on placebo, but none were classified as severe.

The Outcomes Gap: What We Know and Don't Know

FOURIER provides a completed, positive cardiovascular outcomes trial. ORION-4, the inclisiran outcomes trial enrolling approximately 15,000 patients with prior MI or stroke, is ongoing. Interim cardiovascular event data are expected in 2025. Until ORION-4 reports, direct outcomes comparison between the two agents cannot be made from randomized controlled data. All current claims about inclisiran's cardiovascular benefit are mechanistic extrapolations from LDL-C lowering, not direct trial evidence. Clinicians should be transparent with patients about this distinction.

Real-World Evidence: Registry and Health System Data

Adherence in Clinical Practice

This is where the two drugs diverge most sharply outside of a trial context. In the FOURIER trial, adherence was protocol-enforced. Real-world adherence to biweekly or monthly injectables is considerably lower. A 2022 analysis of U.S. Commercial insurance claims found that only 44% of patients initiating a PCSK9 monoclonal antibody (evolocumab or alirocumab) maintained a medication possession ratio above 0.80 at 12 months. Injection fatigue, auto-injector anxiety, and insurance prior authorization hurdles all contributed to discontinuation.

Inclisiran's twice-yearly dosing, particularly when administered in a cardiology or primary care office, may change this calculus. A U.K. National Health Service real-world program deployed inclisiran through GP practices starting in 2023. Early published audit data from approximately 800 patients showed a 12-month persistence rate above 85%, compared with historical PCSK9 monoclonal antibody persistence rates of 50-60% in the same health system. The difference is partly logistical: when a nurse administers the injection at a scheduled appointment, the patient does not need to remember, fill a prescription, or inject themselves.

LDL-C Goal Achievement in the Real World

Both agents achieve LDL-C reductions in the real world that are modestly lower than in trials, consistent with typical efficacy-effectiveness gaps. A 2023 observational analysis from an integrated U.S. Health system (N=412 patients on evolocumab) found a mean LDL-C reduction of 51% at 12 months, with 64% of patients reaching LDL-C <70 mg/dL and 38% reaching <55 mg/dL. Published real-world inclisiran cohorts, though smaller and shorter in follow-up given its 2021 approval, show comparable LDL-C reductions of 48-53% at six months in patients adherent to the dosing schedule.

Head-to-Head Real-World Comparison: What Is Currently Available

No randomized head-to-head trial comparing evolocumab and inclisiran has been completed. Indirect comparison meta-analyses suggest the two agents are statistically indistinguishable in LDL-C lowering when measured at steady state, with overlapping 95% confidence intervals in network meta-analyses. A 2024 network meta-analysis published in the European Heart Journal included 12 PCSK9 inhibitor trials and found inclisiran and evolocumab produced equivalent LDL-C reduction (mean difference 3.1 mg/dL, 95% CI -2.4 to 8.6 mg/dL, P=0.27).

The HealthRX clinical team uses a four-factor decision framework for choosing between the two agents in practice: (1) patient injection self-efficacy, (2) prior authorization pathway with the patient's insurer, (3) availability of in-office inclisiran administration through the prescribing practice, and (4) whether a completed outcomes trial is required for clinical confidence. Patients with high self-efficacy, flexible insurance, and no prior authorization issues may do equally well on either agent. Patients with low adherence history, needle anxiety, or logistical barriers are often better served by the in-office, twice-yearly inclisiran model.

Dosing, Administration, and Storage

Evolocumab Dosing Options

Evolocumab offers more dosing flexibility. The approved regimens are:

• 140 mg subcutaneously every two weeks (single prefilled syringe or auto-injector)
• 420 mg subcutaneously once monthly (three consecutive 140 mg injections within 30 minutes, or the SureClick auto-injector designed for three-injection delivery)

Storage is in the refrigerator at 36-46°F. Each individual 140 mg device can be kept at room temperature (up to 77°F) for up to 30 days. Patients who travel frequently often prefer this flexibility.

Inclisiran Dosing Schedule

Inclisiran 284 mg is given as a single subcutaneous injection on day 1, day 90 (plus or minus 30 days), and every 180 days thereafter. Missed doses can be given if the next scheduled dose is more than three months away; otherwise, the patient resumes the original schedule. Storage is refrigerated, and the drug should not be frozen.

The label allows inclisiran to be administered by a healthcare provider, which has driven the in-office administration model in the U.K. And is increasingly adopted by U.S. Cardiology practices billing under the medical benefit rather than the pharmacy benefit.

Injection Site Reactions

Both drugs cause injection-site reactions at rates low enough not to drive discontinuation in most patients. In FOURIER, injection-site reactions occurred in fewer than 1% of evolocumab patients. In ORION-10/11, the inclisiran rate was 2.6% vs. 0.9% placebo. No anaphylaxis was reported in either trial's pre-specified safety datasets.

Safety Profiles: What Real-World Reporting Adds

Neurocognitive Safety

Early post-marketing reports raised questions about PCSK9 inhibition and cognitive function, given that PCSK9 is expressed in the brain. The EBBINGHAUS trial, a pre-specified substudy of FOURIER, enrolled 1,204 patients and administered structured neuropsychological testing at multiple timepoints. Executive function, memory, and attention scores were no different between evolocumab and placebo groups at 19 months of follow-up. No equivalent dedicated neurocognitive trial has been completed for inclisiran, but given the mechanism (PCSK9 mRNA silencing confined to the liver via GalNAc targeting), CNS penetration is not expected.

Diabetes Risk

Neither PCSK9 monoclonal antibodies nor inclisiran have been associated with increased new-onset diabetes in controlled trial data. This contrasts with statins, where a modest increase in diabetes risk (approximately 10% relative risk increase with moderate-intensity statins per the JUPITER trial subgroup analyses) has been documented. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol notes: "PCSK9 inhibitors have not been shown to increase the risk of new-onset diabetes mellitus in trial populations followed up to 3.4 years." [3]

Liver and Renal Safety

Neither agent requires dose adjustment for mild-to-moderate hepatic impairment. Evolocumab is not recommended in severe hepatic impairment (Child-Pugh C). Inclisiran is not recommended in severe hepatic impairment either, given limited data. Both agents are renally cleared to a minimal degree, and no dose adjustment is required for renal impairment, including dialysis patients.

When to Switch from Repatha to Leqvio

Clinical Reasons to Switch

The most common clinical reason to consider switching an established evolocumab patient to inclisiran is documented non-adherence. If a patient is missing more than two doses per quarter and their LDL-C is not at goal, the biweekly injection burden is likely contributing. Switching to an in-office, twice-yearly regimen removes the daily or biweekly patient burden from the equation.

A second reason is patient preference for fewer self-injections. Some patients tolerate the initial autoinjector experience but develop fatigue or anxiety after months of use. The twice-yearly schedule is meaningfully different from a quality-of-life standpoint.

A third scenario is a payer-driven switch. Some commercial and Medicare plans have moved inclisiran to a preferred tier for PCSK9 inhibitors, particularly as hospitals and health systems negotiate inclusion under the medical benefit. In those cases, switching can reduce out-of-pocket costs substantially.

What to Expect When Switching

LDL-C does not rebound during a structured switch. If the last evolocumab dose was given on schedule, LDL-C is suppressed at the time inclisiran initiation begins. The standard practice is to give the first inclisiran dose at or near the time the next evolocumab dose would have been due, then follow the standard inclisiran schedule (day 1, day 90, every 180 days). Expect a modest transitional rise in LDL-C of approximately 5-10 mg/dL in the first four weeks as evolocumab clears and inclisiran's RISC-mediated suppression builds, though this has not been shown to increase clinical event risk over short intervals.

Situations Where Evolocumab May Remain Preferable

Inclisiran's label currently excludes pregnancy and breastfeeding (FDA category not assigned; the manufacturer advises against use given lack of data). Evolocumab also has pregnancy data limitations, but it has a longer post-market history. For patients planning pregnancy, neither agent should be continued without specialist review.

Patients who require frequent LDL-C titration checks (for example, those with very high baseline LDL-C who may need confirmation of an adequate response within eight weeks) may benefit from evolocumab's faster pharmacokinetic profile, since inclisiran's effect builds over 90 days to steady state.

Cost, Coverage, and Access

U.S. Insurance Field

Both evolocumab and inclisiran require prior authorization from most commercial plans and Medicare Part D (for the pharmacy benefit) or Medicare Part B (for the medical benefit, when administered in-office). List prices as of 2025 are approximately $6,500-7,000 per year for evolocumab and approximately $6,900 per year for inclisiran in the U.S. Market. Amgen's Repatha copay card reduces out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. Novartis offers a similar copay assistance program for Leqvio.

Medical Benefit vs. Pharmacy Benefit

A structural advantage for inclisiran is that it can be billed under the medical benefit (CPT code 96401 for chemotherapy administration, or the drug-specific HCPCS code) when given in a physician office or outpatient clinic. This means patients enrolled in Medicare Part B, which has no annual out-of-pocket drug cap, may access inclisiran at 20% coinsurance after meeting their deductible. For some patients, this is cheaper than navigating Medicare Part D's coverage gap for a self-injected PCSK9 antibody.

Guideline Context

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol places PCSK9 inhibitors as a Class I recommendation (Level of Evidence: A) for adults with clinical ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy [3]. The guideline does not distinguish between evolocumab and inclisiran at the level of the recommendation, treating them as therapeutically interchangeable for LDL-C lowering purposes. The ESC/EAS 2021 dyslipidemia guidelines similarly provide a Class I recommendation for PCSK9 inhibition in very-high-risk patients who have not reached their LDL-C goal on statin plus ezetimibe.

The ESC/EAS guidelines state: "In patients at very high cardiovascular risk not achieving their LDL-C goal with a maximum tolerated statin dose, in combination with ezetimibe, a PCSK9 inhibitor is recommended." [4] That recommendation covers both mechanism classes.